Full Press Release Details
to Develop Strategic
Investor Relations Program
Investor Awareness and Develop World-Class Communications Infrastructure as Company Executes Aggressive Growth Strategy
BELGRADE, Mont. Feb. XX, 2012 - Bacterin International Holdings,
Inc. (NYSE Amex: BONE), a leader in the development of revolutionary bone graft material and antimicrobial coatings for medical
applications, has engaged Hayden IR, a 15-year-old, highly recognized, national investor relations firm, to develop and
implement a strategic investor relations program and raise its visibility and strengthen its relationships with the investment
"Over the last eight quarters, Bacterin has delivered record
revenue by manufacturing and marketing superior bone graft material, biological scaffolds and related medical devices while developing
bioactive anti-microbial coatings for implantable devices," commented Guy Cook, CEO of Bacterin. "We expect our outstanding
growth to continue, compounded and complemented by key drivers, including our expanded direct sales force, increased product lines,
accelerated use among surgeons, augmented geographic footprint which adds international markets, broadened core technology that
we are leveraging into additional revolutionary products, scientific peer reviewed studies to be published and fortified strategic
relationships and distribution partnerships. Accordingly, we believe it is an ideal time to retain a national investor relations
firm to help us target an expanding investor audience and ensure we are communicating effectively with current and potential shareholders.
We look forward to working with the team of professionals at Hayden IR to execute this important goal."
With offices in New York, Phoenix, Minneapolis and San Diego, Hayden
IR provides a comprehensive range of investor relations services to a growing list of clients. For more than a decade, Hayden IR
has been a recognized leader in driving market recognition and creating sustainable competitive advantages for more than 200 micro-
and small-cap companies. Hayden delivers expertise and professionalism in such areas as investor management, relationship building,
awareness campaigns, online presence and corporate identity.
James Carbonara, Regional VP, in Hayden IR's New York City
office, added, "Bacterin represents a compelling opportunity, doubling revenue the last two years to a guided $30 - $32 million
for 2011. Management expects continued rapid growth for 2012, with guidance of $53 - $56 million and generating almost 75-80% gross
margins. Analysts are projecting operating margin expansion to the mid-20% range, if not higher', leveraging its sales
force and establishing infrastructure to support $120 million to $175 million in revenue. Bacterin's broad product portfolio
addresses a $7 billion market with key drivers in place to continue to capture market share as well as a possible call option'
opportunity with OsteoSponge SC. Hayden IR believes that it is a great time for investors to be looking at Bacterin as it trades
at 2.2 times the low-end of 2012 revenue guidance, lower than comparable companies in the field, in spite of a more robust growth
The team at Hayden IR looks forward to articulating this opportunity
to the professional investment community."
About Bacterin International Holdings
Bacterin International Holdings, Inc. (NYSE Amex: BONE) develops,
manufactures and markets biologics products to domestic and international markets. Bacterin's proprietary methods optimize the
growth factors in human allografts to create the ideal stem cell scaffold to promote bone, subchondral repair and dermal growth.
These products are used in a variety of applications including enhancing fusion in spine surgery, relief of back pain, promotion
of bone growth in foot and ankle surgery, promotion of cranial healing following neurosurgery and subchondral repair in knee and
other joint surgeries. Bacterin's Medical Device division develops, employs, and licenses bioactive coatings for various medical
device applications. Bacterin's strategic coating initiatives include antimicrobial coatings designed to inhibit biofilm formation
and microbial contamination. For further information, please visit www.bacterin.com.
Important Cautions Regarding Forward-looking Statements
This news release contains certain disclosures that may be deemed
forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to significant
risks and uncertainties. Forward-looking statements include statements that are predictive in nature, that depend upon or refer
to future events or conditions, or that include words such as "continue," "efforts," "expects," "anticipates,"
"intends," "plans," "believes," "estimates," "projects," "forecasts,"
"strategy," "will," "goal," "target," "prospects," "potential," "optimistic,"
"confident," "likely," "probable" or similar expressions or the negative thereof. Statements of historical
fact also may be deemed to be forward-looking statements. We caution that these statements by their nature involve risks and uncertainties,
and actual results may differ materially depending on a variety of important factors, including, among others: the Company's ability
to launch beta and full product releases, the Company's ability to obtain FDA concurrence use for anti-microbial coatings in a
timely manner; the Company's ability to meet its obligations under existing and anticipated contractual obligations; the Company's
ability to develop, market, sell and distribute desirable applications, products and services and to protect its intellectual property;
the ability of the Company's sales force to achieve expected results; the ability of the Company's customers to pay and the timeliness
of such payments, particularly during recessionary periods; the Company's ability to obtain financing as and when needed; changes
in consumer demands and preferences; the Company's ability to attract and retain management and employees with appropriate skills
and expertise; the impact of changes in market, legal and regulatory conditions and in the applicable business environment, including
actions of competitors; and other factors. Additional risk factors are listed in the Company's Annual Report on Form 10-K under
the heading "Risk Factors." The Company undertakes no obligation to release publicly any revisions to any forward-looking
statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except
James Carbonara, Regional Vice President, 646-755-7412
Brett Maas, 646-536-7331